Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 15/20 | 0.70 |
| ▸ | CDC7 | O00311 | 3/20 | 0.64 |
| ▸ | DBF4 | Q9UBU7 | 3/20 | 0.64 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL611492 | 0.87 | IKBKB (0.52) | IKBKBCDC7DBF4 | |
| SCHEMBL613270 | 0.85 | KDM4E (0.57) | IKBKBCDC7DBF4 | |
| SCHEMBL614239 | 0.85 | CDC7 (0.59) | IKBKBCDC7DBF4JAK2CCNE1 | |
| SCHEMBL613690 | 0.85 | CDC7 (0.59) | IKBKBCDC7DBF4JAK2CCNE1 | |
| SCHEMBL613122 | 0.82 | CDC7 (0.57) | IKBKBCDC7DBF4JAK2CCNE1 | |
| SCHEMBL614144 | 0.80 | CDC7 (0.54) | IKBKBCDC7DBF4JAK2CDK2 | |
| SCHEMBL612267 | 0.78 | CDC7 (1.00) | IKBKBCDC7DBF4MAP2K3JAK2 | |
| SCHEMBL614262 | 0.78 | CDC7 (0.65) | IKBKBCDC7DBF4JAK2CCNE1 | |
| Hydrochloric Acid SCHEMBL612294 | 0.75 | IKBKB (0.56) | IKBKBCDC7DBF4CCNE1CDK2 | |
| SCHEMBL613722 | 0.72 | KDM4E (0.52) | IKBKBCDC7DBF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403857-B1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| EP-2403857-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2012-01-11 | — | — | EP | disclosed |
| WO-2010101302-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | CDC7, CDK7, DTYMK | IKBKB 993/4885CDC7 1/4885DBF4 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.